ENCALM: A Study of ENX-102 as a Monotherapy Treatment in Patients With Generalized Anxiety Disorder

Completed · Phase 2 · Has a placebo group

Conditions studied: Generalized Anxiety Disorder

In brief

The ENCALM trial is designed to evaluate the efficacy and safety of ENX-102 in patients diagnosed with generalized anxiety disorder (GAD)

Key facts

Study ID
NCT05749055
Run by
Engrail Therapeutics INC
People needed
252
Starts
2023-07-03
Expected to finish
2025-09-18
Last updated by the study team
2025-09-25

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.